Ratings by Canaccord (Sumant Kulkarni)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/18/2026 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 2/12/2026 | Neurocrine Bio. | NBIX | Maintain | Buy (Buy) |
|
Details | ||
| 2/9/2026 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 11/28/2025 | Neurocrine Bio. | NBIX | Maintain | Buy (Buy) |
|
Details | ||
| 11/20/2025 | Cybin Inc. | CYBN | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2025 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2025 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 9/12/2025 | Biogen | BIIB | Maintain | Buy (Buy) |
|
Details | ||
| 8/18/2025 | Clene, Inc. | CLNN | Maintain | Buy (N/A) |
|
Details | ||
| 7/29/2025 | CervoMed | CRVO | Maintain | Buy (N/A) |
|
Details | ||
| 7/8/2025 | Cybin Inc. | CYBN | Maintain | Buy (N/A) |
|
Details | ||
| 6/17/2025 | Sage Therapeutics | SAGE | Maintain | Hold (N/A) |
|
Details | ||
| 5/6/2025 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2025 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2025 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2025 | CervoMed | CRVO | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2025 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2025 | Voyager Therapeutics | VYGR | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2025 | Intra-Cellular Therapies | ITCI | Upgrade | Buy (Hold) |
128.25 (131.87) |
2.82% | Details | |
| 2/28/2025 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 2/13/2025 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 2/12/2025 | Sage Therapeutics | SAGE | Maintain | Hold (N/A) |
|
Details | ||
| 2/12/2025 | Cybin Inc. | CYBN | Maintain | Buy (N/A) |
|
Details | ||
| 2/7/2025 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 1/30/2025 | Intra-Cellular Therapies | ITCI | Downgrade | Hold (Buy) |
127.02 (131.87) |
3.82% | Details | |
| 1/6/2025 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 12/11/2024 | CervoMed | CRVO | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2024 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2024 | Cybin Inc. | CYBN | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2024 | Clene, Inc. | CLNN | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2024 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 10/10/2024 | Clene, Inc. | CLNN | Maintain | Buy (Buy) |
|
Details | ||
| 10/4/2024 | Clene, Inc. | CLNN | Maintain | Buy (N/A) |
|
Details | ||
| 9/23/2024 | Cybin Inc. | CYBN | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2024 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Buy (Buy) |
|
Details | ||
| 8/30/2024 | BioXcel Therapeutics | BTAI | Maintain | Buy (Buy) |
|
Details | ||
| 8/6/2024 | Sage Therapeutics | SAGE | Maintain | Hold (N/A) |
|
Details | ||
| 8/6/2024 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 8/5/2024 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 8/2/2024 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 6/27/2024 | Cybin Inc. | CYBN | Maintain | Buy (N/A) |
|
Details | ||
| 6/19/2024 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 6/13/2024 | Cara Therapeutics | CARA | Downgrade | Hold (Buy) |
0.66 (5.32) |
706.06% | Details | |
| 5/2/2024 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 4/26/2024 | Sage Therapeutics | SAGE | Maintain | Hold (N/A) |
|
Details | ||
| 4/25/2024 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 4/23/2024 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 4/8/2024 | CervoMed | CRVO | Maintain | Buy (N/A) |
|
Details | ||
| 3/14/2024 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 2/23/2024 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 2/22/2024 | Cybin Inc. | CYBN | Maintain | Buy (N/A) |
|
Details | ||
| 2/20/2024 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 2/15/2024 | CervoMed | CRVO | New Coverage | Buy (N/A) |
14.13 (4.11) |
-70.91% | Details | |
| 2/8/2024 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 11/15/2023 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 11/9/2023 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2023 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 9/12/2023 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 8/22/2023 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 8/16/2023 | Zynerba Pharmaceuticals | ZYNE | Downgrade | Hold (Buy) |
1.35 (1.30) |
-3.7% | Details | |
| 8/15/2023 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2023 | Cara Therapeutics | CARA | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2023 | Sage Therapeutics | SAGE | Downgrade | Hold (Buy) |
16.75 (8.68) |
-48.18% | Details | |
| 8/4/2023 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 8/2/2023 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 7/3/2023 | Cybin Inc. | CYBN | Maintain | Buy (N/A) |
|
Details | ||
| 6/22/2023 | Clene, Inc. | CLNN | Maintain | Buy (N/A) |
|
Details | ||
| 6/12/2023 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 5/16/2023 | Zynerba Pharmaceuticals | ZYNE | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2023 | Neurocrine Bio. | NBIX | Upgrade | Buy (Hold) |
97.10 (128.13) |
31.96% | Details | |
| 3/29/2023 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2023 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 3/7/2023 | Cara Therapeutics | CARA | Maintain | Buy (N/A) |
|
Details | ||
| 2/7/2023 | Neurocrine Bio. | NBIX | Maintain | Hold (N/A) |
|
Details | ||
| 11/11/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 11/10/2022 | Kempharm | KMPH | Maintain | Buy (N/A) |
|
Details | ||
| 11/4/2022 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2022 | Neurocrine Bio. | NBIX | Maintain | Hold (N/A) |
|
Details | ||
| 10/26/2022 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 10/13/2022 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 10/4/2022 | Clene, Inc. | CLNN | Maintain | Buy (N/A) |
|
Details | ||
| 9/15/2022 | Kempharm | KMPH | New Coverage | Buy (N/A) |
6.08 (5.81) |
-4.44% | Details | |
| 8/5/2022 | Neurocrine Bio. | NBIX | Maintain | Hold (N/A) |
|
Details | ||
| 5/2/2022 | Clene, Inc. | CLNN | New Coverage | Buy (N/A) |
2.59 (5.36) |
106.95% | Details | |
| 4/25/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 4/7/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 3/14/2022 | Cara Therapeutics | CARA | Maintain | Buy (N/A) |
|
Details | ||
| 3/9/2022 | Voyager Therapeutics | VYGR | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2022 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2022 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2022 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 1/28/2022 | Cortexyme Inc. | CRTX | Downgrade | Hold (Buy) |
5.59 (1.95) |
-65.12% | Details | |
| 1/3/2022 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2022 | Voyager Therapeutics | VYGR | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2022 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 12/20/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 11/1/2021 | Cara Therapeutics | CARA | New Coverage | Buy (N/A) |
16.95 (0.66) |
-96.11% | Details | |
| 10/27/2021 | Cortexyme Inc. | CRTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/16/2021 | Cortexyme Inc. | CRTX | Maintain | Buy (N/A) |
|
Details | ||
| 8/27/2021 | Cybin Inc. | CYBN | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2021 | Neurocrine Bio. | NBIX | Downgrade | Hold (Buy) |
92.69 (128.13) |
38.23% | Details | |
| 8/3/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 7/27/2021 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 7/27/2021 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 4/1/2021 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 3/22/2021 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (Buy) |
|
Details | ||
| 11/16/2020 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2020 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2020 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 7/1/2020 | Zynerba Pharmaceuticals | ZYNE | Maintain | Buy (N/A) |
|
Details | ||
| 6/18/2020 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 6/10/2020 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2020 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2020 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 2/21/2020 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 1/27/2020 | Biogen | BIIB | Upgrade | Buy (Hold) |
284.21 (184.87) |
-34.95% | Details | |
| 11/13/2019 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2019 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 10/31/2019 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 10/23/2019 | Biogen | BIIB | Maintain | Hold (N/A) |
|
Details | ||
| 10/7/2019 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 9/16/2019 | Alder Biopharm | ALDR | Downgrade | Hold (Buy) |
10.06 (18.88) |
87.67% | Details | |
| 9/10/2019 | Acadia Pharmaceuticals | ACAD | Upgrade | Buy (Hold) |
23.80 (22.16) |
-6.89% | Details | |
| 8/26/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 7/22/2019 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 7/22/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 6/25/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 6/18/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 6/17/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2019 | Cortexyme Inc. | CRTX | New Coverage | Buy (N/A) |
26.65 (1.95) |
-92.68% | Details | |
| 4/22/2019 | Zynerba Pharmaceuticals | ZYNE | New Coverage | Buy (N/A) |
8.09 (1.30) |
-83.93% | Details | |
| 4/15/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 4/8/2019 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 3/21/2019 | Biogen | BIIB | Downgrade | Hold (N/A) |
320.59 (184.87) |
-42.33% | Details | |
| 3/14/2019 | Alder Biopharm | ALDR | Maintain | Buy (N/A) |
|
Details | ||
| 3/8/2019 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2019 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 12/10/2018 | Acadia Pharmaceuticals | ACAD | New Coverage | Hold (N/A) |
18.91 (23.80) |
25.86% | Details | |
| 11/21/2018 | Neurocrine Bio. | NBIX | New Coverage | Buy (N/A) |
87.33 (128.13) |
46.72% | Details | |
| 11/14/2018 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details |
